



BioSpectrum Ranking Survey: Rank 3: Jubilant Life Sciences

15 September 2016 | Features | By BioSpectrum Bureau

BioSpectrum Ranking Survey: Rank 3: Jubilant Life Sciences

Jubilant Life Sciences Limited

Co-chairman and MD: Hari S Bhartia

Total revenue: Rs 3,144 crore (Life Sciences business only)

Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in manufacturing and supply of APIs, solid dosage formulations, radiopharmaceuticals, allergy therapy products, advance intermediates, fine ingredients, crop science ingredients, life science chemicals and nutritional products. It also provides services in contract manufacturing of sterile injectables and drug discovery solutions. The company's strength lies in its unique offerings of pharmaceutical and life sciences products and services.

Jubilant Life Sciences revenue for the FY 15-16 is Rs 3,144 crore.

Over the years, Jubilant Life Sciences has extended its footprint beyond India in the USA, Canada, Europe, and other countries across the globe.

It has also expanded the business by building capabilities internally, through strategic expansions and acquisitions. This resulted in a network of 7 world class manufacturing facilities in India and 4 in North America and a team of around 6,100

multicultural people across the globe with ~ 1,200 in North America and ~900 in R&D.

In the last fiscal, Jubilant Biosys, a Bengaluru-based subsidiary of Jubilant Life Sciences, and Sanofi Deutschland GmbH, Frankfurt, Germany, announced a strategic alliance to discover and develop small molecule inhibitors for multiple targets in the metabolic disorders therapeutic area. The research alliance is aimed at developing therapeutic small molecules that will address the unmet needs in diabetes and obesity.

As per the terms of the agreement, Jubilant shall provide Sanofi integrated drug discovery and early development services across computational, synthetic chemistry, biology, GLP/GMP services, to identify lead candidates and demonstrate clinical proof of mechanism in the metabolic disorders therapeutic areas. The research for the projects, which has been initiated, will be undertaken primarily at state-of-the-art R&D labs of Jubilant Biosys (Bengaluru, India) and Jubilant Chemsys (Noida, India).